AVANZA_57891.jpg

Exactech Schedules First Quarter 2017 Earnings Release and Conference Call

Posted On April 12, 2017 By OrthoSpineNews In Financial /  

April 12, 2017

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic materials for extremities, hip and knee will release its first quarter 2017 financial results on Tuesday, April 25, 2017. A copy of the earnings release will be available at http://www.hawkassociates.com.

The company will hold a conference call with CEO David Petty and key members of the management team on Wednesday, April 26 at 10:00 a.m. Eastern Time. The call will cover Exactech’s first quarter 2017 results. Mr. Petty will open the conference call and a question-and-answer session will follow.

To participate in the call, dial 877-874-1569 any time after 9:50 a.m. Eastern on April 26. International and local callers should dial 719-325-4888. A live webcast of the call will be available at http://www.hawkassociates.com/profile/exac.cfm or http://public.viavid.com/index.php?id=123876.

This call will be archived for approximately 90 days.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.

A current investment profile on Exactech (Nasdaq: EXAC) is available online at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

Contacts

Exactech, Inc.
Investor contacts
Jody Phillips, 352-377-1140
Executive Vice President of Finance &
Chief Financial Officer
or
Hawk Associates
Julie Marshall or Frank Hawkins, 305-451-1888
EXAC@hawkassociates.com
or
Media contacts
Exactech
Priscilla Bennett, 352-377-1140
Vice President, Corporate & Marketing Communication

Read More
HTH-0425-OutpatientSurgery-2.jpeg

Here’s why more patients turn to outpatient surgical clinics for complex procedures

Posted On April 12, 2017 By OrthoSpineNews In Financial /  

BY JOHN STARK for The Bellingham Herald

Thanks to advances in medical technology, many surgery patients who would once have faced a few nights in a hospital are now getting complex procedures done at outpatient clinics that can get them in and out in less than a day.

The trend toward replacing lengthy hospital stays with an outpatient approach began in the 1970s, grew steadily and still appears to be gaining momentum. There is much more at stake than patient convenience: Outpatient surgery is far less costly to patients, insurers and the government programs that pay medical bills for millions of people.

That’s because hospitals must charge enough to cover their extensive overhead costs, which are far less in an outpatient clinic.

Pam Novotny, administrator at Bellingham Ambulatory Surgery Center at 2075 Barkley Boulevard, provided some examples:

▪ For cataract surgery, Medicare reimburses a hospital about $1,800. An ambulatory surgery center gets less about $1,100.

▪ For inguinal hernia repair, a hospital gets about $2,900, while a surgery center gets about $1,700.

▪ A breast lumpectomy costs Medicare about $2,500 in a hospital, compared to about $1,200 at a surgery center.

Gary Richberg is administrator at Pacific Rim Outpatient Surgery Center, 3009 Squalicum Parkway next to Peace Health St. Joseph Medical Center. Richberg said Pacific Rim is Bellingham’s largest surgery center, with about 5,000 surgeries performed there each year.

Richberg estimated that about 35 percent of procedures at Pacific Rim are knee and hip surgeries, including full joint replacements that once involved costly hospital stays of three to four days. Medical and professional journals report that an increasing number of such surgeries are being done at surgical centers instead of in hospitals, mostly because the cost is thousands of dollars less.

 

READ THE REST HERE

Read More
FLXfit-technology.jpg

Expanding Orthopedics Inc. to Present Clinical Information With FLXfit™ at the ISSAS Conference in Boca Raton

Posted On April 12, 2017 By OrthoSpineNews In Spine /  

OR AKIVA, Israel, April 12, 2017 /PRNewswire/ —

Expanding Orthopedics Inc. (EOI), a privately held medical device company focused on developing and commercializing innovative expandable devices for spine surgery, is excited to announce that clinical experience with the FLXfit™, world’s first articulating and lordotic expandable cage, which will be presented by two distinguished surgeons at the International Society for the Advancement of Spine Surgery (ISASS) Meeting in Boca Raton, FL.

Dr. Marc Weinstein, from the Center for Spinal Disorders at the Florida Orthopaedic Institute in Tampa, will have a podium presentation “Use of a Novel 3-D Titanium Alloy Lordotic Expandable Cage Improves Segmental Lordosis after TLIF Greater than with a Static Lordotic Cage. Dr. Weinstein commented, “The FLXfit enables a unique, in-situ lordosis correction allowing to dial in the lordosis angle and to fit it to the patient’s anatomy.” Moreover, “The FLXfitTM cage effectively allows for larger cage in the interbody space once expanded.” Dr. Weinstein added, “Our study has shown significantly improved segmental lordosis was achieved using FLXfitTM with TLIF when compared to a static cage. He concludes, “We are in the midst of a clinical study which will provide a more thorough investigation of this unique device and demonstrate its clinical value for our patients.”

Dr. Raphael Roybal, from the Spine Institute at Chatham Orthopaedics, Savannah, GA., will have a poster presentation “Improvement in Sagittal Alignment and ODI Scores in Patients Treated with MIS TLIF Using a Lordotic Expandable Cage versus a Fixed Lordotic cage”. He noted, “The use of the FLXfit™ expandable cage demonstrated increased correction of the sagittal alignment post-operatively compared to a fixed angle banana cage.” Dr. Roybal added, “The combination of a large footprint device, controlled lordotic expansion and an easy to use instrumentation makes it an optimal solution for my patients.”

Mr. Ofer Bokobza, CEO of Expanding Orthopedics, said that “We are excited to present at this important ISSAS event with two renowned surgeons as Dr. Roybal and Dr. Weinstein. This continues to reinforce the clinical benefits of this novel device and its potential contribution to sagittal alignment.” Mr. Bokobza stated that, “We are excited about the momentum and growth of the FLXfitTMin the US and are continuing to monitor and collect clinical data in more US centers.”

About Expanding Orthopedics Inc.

Expanding Orthopedics Inc. is medical device company developing and marketing innovative products designed to address unmet clinical needs for spine care and improve long-term patients’ outcome. The company is led by a seasoned management team, and is backed by prominent spine surgeons. EOI owns a broad patent portfolio of anatomically fit, expandable devices for enhanced stability through a minimally invasive approach.

Contact info:
David Elkaïm
Vice President
Sales and Marketing
E-mail: david@xortho.com
Phone: +1(347)3219683

SOURCE Expanding Orthopedics Inc. (EOI)

Read More
simplify_disc2.png

Simplify Medical Announces First Patient Treated in U.S. Pivotal Trial Of MRI-Optimized Cervical Artificial Spinal Disc at Two Adjacent Levels

Posted On April 12, 2017 By OrthoSpineNews In Spine, Top Stories /  

April 12, 2017

SUNNYVALE, Calif.–(BUSINESS WIRE)–Simplify Medical, Inc., maker of the Simplify® cervical artificial disc, today announced that the first patient has been treated in the device’s pivotal clinical trial studying its use in two adjacent levels of the spine as a treatment for cervical degenerative disc disease. The Simplify Disc is designed to be clearly viewed on magnetic resonance imaging (MRI) without the artifact that can result from metal used in typical spine implants, potentially protecting patients from radiation associated with computed tomography (CT) scans.

Following the first case at Texas Back Institute, Simplify Disc IDE study investigator John Peloza, MD said, “Disc implantation went smoothly and the patient is doing quite well.” Dr. Peloza, medical director of the Center for Spine Care, continued, “I look forward to studying the use of the Simplify Disc at two levels, in collaboration with the Texas Back Institute team. I believe the Simplify Disc’s anatomic design with lower heights can help minimize overdistraction, which may improve outcomes in multi-level procedures.”

Richard Guyer, MD, chairman of the Texas Back Institute Foundation and national co-primary investigator for the study, said, “We are excited to start the Simplify Disc Two-Level IDE study. The device is made of materials designed to optimize its viewing and viewing of the adjacent spinal canal on MRI without artifact. This may eliminate or minimize the use of post-operative CT scans and reduce the risk of the associated radiation to the patient.”

The prospective, randomized controlled Simplify Disc pivotal trial will encompass up to 215 patients at up to 15 centers and will compare cervical implantation of two contiguous discs from C3 to C7 with two-level cervical fusion surgery. The composite primary endpoint includes functional improvement, pain relief and safety. The national co-principal investigators are Domagoj Coric, MD, chief of the department of neurosurgery, Carolinas Medical Center, and Dr. Guyer. For information about eligibility or enrollment in the two-level pivotal trial, please visit http://www.simplifytrial.com/.

While magnetic resonance imaging (MRI) is widely used pre-operatively for surgical planning, spine surgeons often switch to CT post-operatively in order to accommodate metal components, which can make it difficult to view the devices, as well as the facets and adjacent levels. However, CT scans have been shown to expose patients to ionizing radiation that equates to 400 to 550 chest X-rays per scan.

Composed of primarily non-metal materials (PEEK-on-ceramic), the Simplify Disc is designed to be viewed on MRI in order to minimize patient exposure to radiation. With no metal in its articulating components, the disc is also designed for low levels of wear to optimize long-term durability. Implantation of the Simplify Disc is accomplished in a simple, three-step procedure. The Simplify Disc is also anatomically designed with low height implant options to accommodate patients with smaller cervical disc spaces, making it ideal for women and certain regional populations. The device is considered MRI-conditional, posing no known hazard in an MRI environment within prescribed conditions of use.

“We have designed the Simplify Disc to be responsive to surgeons’ needs, providing them with the potential to improve patient outcomes,” said David Hovda, Simplify Medical Chief Executive Officer. “We are enthusiastic about moving forward with the pivotal trial.”

The Simplify Disc is also enrolling patients in a second pivotal trial comparing one-level cervical implantation of the disc between C3 to C7 with cervical fusion surgery from a historical nonconcurrent control group. More information about the one-level clinical trial is available at www.SimplifyTrial.com.

The Simplify Disc has received the CE Mark and has been used to treat more than 600 patients outside the U.S. over the last three years. Early clinical data has shown substantial improvement in patient pain scores and functional improvement after treatment.

ABOUT SIMPLIFY MEDICAL

Simplify Medical is focused on cervical spinal disc arthroplasty, using innovative, MRI-friendly materials designed to decrease the need for ionizing radiation and enhance patient options. Simplify Medical is located in Sunnyvale, California. To learn more, visit http://www.simplifymedical.com/.

Caution: The Simplify Disc is an Investigational device in the United States and is limited by law to investigational use.

Contacts

Chronic Communications, Inc.
Michelle McAdam, (949) 545-6654
michelle@chronic-comm.com

Read More
maxresdefault-2.jpg

Mazor Robotics Receives FDA Clearance for Spinal Deformity Correction Planning Software for the Mazor X Surgical Assurance Platform

Posted On April 12, 2017 By OrthoSpineNews In Regulatory, Robotics /  

April 12, 2017

CAESAREA, Israel–(BUSINESS WIRE)–Mazor Robotics Ltd. (TASE: MZOR)(NASDAQGM: MZOR), a pioneer and leader in the field of surgical guidance systems, has received FDA clearance for its Mazor X Align™ software. Mazor X Align is designed to assist surgeons in planning spinal deformity correction and spinal alignment for procedures performed with the Mazor X Surgical Assurance Platform. The new software will be demonstrated during exhibit hours at the 2017 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in Los Angeles, CA, April 22-26.

Mazor X Align leverages Mazor Robotics’ extensive experience in pre-operative planning, image processing, computerized anatomy recognition, and registration of different imaging modalities. It is the latest module to be added to the Mazor X proprietary Pre-operative Analytics software suite, and enables surgeons to create a patient-specific, three-dimensional spinal alignment plan. The 3D plan simulates an entire spine, allowing pre-operative estimation of the impact of a planned surgical correction on the patient’s posture post-operatively, considering segmental range-of-motion and final alignment parameters.

According to Ori Hadomi, CEO of Mazor Robotics, “Mazor X Align is the product of Mazor’s development program and represents our innovative pipeline and visionary team experience. We are dedicated to pushing the envelope bringing to the market advanced products and applications in order to benefit an increasing number of patients suffering from difficult conditions and supporting the medical professionals serving them.”

Mazor X Align will be released to a selection of Mazor X customers in early May. This early release will be followed by a widespread release during the second half of 2017.

During AANS, Mazor Robotics will be hosting the following special presentations at booth #1423:

Presentation: Clinical Experience with Mazor Robotics Guidance Systems
Presenter: Dr. Jae Y. Lim
Date: Monday, April 24
Time: 1:00 – 2:00 pm

Presentation: Initial Case Series with Mazor Robotics’ Next Gen System: Mazor X™
Presenter: Dr. Donald M. Whiting
Date: Monday, April 24
Time: 3:30 – 4:00 pm

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in an accurate and secure manner. For more information, please visit MazorRobotics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the benefits of the Company’s products, the timing of release of Mazor X Align, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on May 2, 2016 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

Contacts

EVC Group
Investors
Michael Polyviou, 212-850-6020
mpolyviou@evcgroup.com
Doug Sherk, 646-445-4800
dsherk@evcgroup.com

Read More
Cyisc9oXgAATyC_.jpg

Brian May Joins Spine Wave as Executive Vice President, Research and Development

Posted On April 12, 2017 By OrthoSpineNews In Spine /  

SHELTON, CT–(Marketwired – April 12, 2017) – Spine Wave, Inc. is a fast growing, privately held company committed to the commercialization of high-quality, innovative medical devices for the treatment of spinal disorders. Spine Wave is pleased to announce that Brian May has joined the Company as Executive Vice President, Research and Development.

Mr. May brings extensive experience in the orthopedics market and was most recently at Zimmer Biomet where he was one of the two directors running Product Development for the Zimmer Biomet Knee Reconstruction business. Brian is a seasoned leader with a proven track record in orthopedic product development. He joined Zimmer in 2015 via the Biomet acquisition where he spent the previous 13 years of his career. Mr. May holds a Bachelor of Science degree from University of Illinois and a Master of Science in Bioengineering from Clemson University.

As Spine Wave continues to expand its portfolio with differentiated products, Mr. May will lead the extensive research and development efforts. “I am pleased to have someone with Brian’s proven leadership ability join the Spine Wave team,” said Mark LoGuidice, Spine Wave’s Chief Executive Officer. “Biomet grew nearly tenfold during Brian’s tenure and that firsthand experience will prove invaluable to Spine Wave as we position ourselves for the next phase of significant growth.”

“I am excited to join Spine Wave, a company with a proven history of developing and commercializing innovative products,” said Mr. May. “Spine Wave has several important product launches scheduled for 2017 which will significantly broaden the company’s offering and which have the potential to generate robust and sustainable growth for the foreseeable future. I look forward to contributing to Spine Wave’s continued growth and evolution.”

About Spine Wave
Spine Wave’s vision is to leverage our intellectual property portfolio and engineering expertise to deliver a steady stream of highly differentiated spinal technologies with a particular emphasis on expandable interbody devices. Spine Wave’s portfolio of expandable products now includes the Velocity® Interbody Device, the Leva® Interbody Device and the StaXx® family of products, of which over 50,000 devices have been implanted. Other novel products in the portfolio include the Annex® Adjacent Level System, the Sniper® Spine System, which has developed a reputation as a leading MIS screw system, and the recently acquired True Position® Pivoting Spacer System which is comprised of a “crescent-style” interbody device and a unique delivery mechanism which simplifies accurate and reproducible placement of the implant. Spine Wave is committed to delivering a robust pipeline in 2017 and 2018 that will allow the company to address every major spine market segment with a highly differentiated offering.

For further information on all the Spine Wave products please visit the Company’s website at www.SpineWave.com.

Contact:
Terry Brennan
Chief Financial Officer
Email contact

203-712-1810

Read More
mma.prnewswire.comAnchor_Orthopedics_Texas_-7a2b837dcbdf78817e88d0223c3c5edbeee9715d.jpg

Texas Back Institute first in the US to provide herniated disc repair using Anchor Orthopedics’ Technology

Posted On April 11, 2017 By OrthoSpineNews In Spine /  

PLANO, TX, April 11, 2017 /PRNewswire/ – Texas Back Institute continues to lead the way in spine surgery by being the first in the US to use the AnchorKnot® Tissue Approximation Kit, a novel technology for use in herniated disc repair.

Dr. Scott L. Blumenthal, board-certified orthopedic spine surgeon, physician executive with Texas Back Institute and Co-Medical Director of Center for Disc Replacement, performed a discectomy procedure on a young patient in February 2017. This patient was the first in the US to undergo herniated disc repair using the AnchorKnot® Kit.

Lumbar disc herniation is one of the most common causes for back surgery, and can occur from injury or disc degeneration.  In both cases, material from a damaged disc presses on the spinal nerve, causing many patients to experience pain, which can significantly decrease their quality of life.  A standard discectomy procedure offers effective relief; however, it commonly results in a defect that until now, has been difficult to repair without specific tools. Studies have shown that 10-15% of patients could suffer a reherniation through this defect.

The Texas Back Institute completed nearly 500 discectomy cases in 2016. Dr. Blumenthal comments that “most discectomy procedures are left to heal through the body’s scar tissue which could take 6 weeks or more, so if approximating the tissue can return patients to function and to rehab earlier then this could be a real benefit to patients.”  Dr. Blumenthal indicates that there has been literature and commercial attempts in the past and “with appropriate studies and follow-up this could be a game changer for patient outcomes.”

“As an experienced medical device company, we have worked closely for numerous years with surgeons to design the AnchorKnot®Tissue Approximation Kit for use in herniated disc repair.  It is a tremendous honor for Anchor Orthopedics to have our first US clinical partner at the Texas Back Institute,” said Neil Godara, General Manager. “Our goal is to design clinically meaningful products that improve the lives of patients around the world. We look forward to offering the AnchorKnot® Tissue Approximation Kit to patients in need of a discectomy procedure, and continuing to collaborate with Dr. Blumenthal and his team at the Texas Back Institute.”

About Anchor Orthopedics

Anchor Orthopedics XT Inc., the developer of the AnchorKnot® Tissue Approximation Kit, aims to provide surgeons with novel solutions that optimize procedures in disc repair in an effort to preserve the biomechanics of the patient and improve surgical outcomes. Our mission is to work closely with surgeons on all aspects of development to create clinical solutions that serve to improve the lives of patients around the world. Anchor Orthopedics XT Inc., located in Mississauga, Canada, is a subsidiary of Baylis Medical Company Inc.

PRM-00194 EN J-1 V-1 © Anchor Orthopedics XT Inc., 2017. Anchor Orthopedics XT and AnchorKnot are trademarks and/or registered trademarks of Anchor Orthopedics XT Inc. in the USA and/or other countries. All other trademarks are the property of their respective owners. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use. The AnchorKnot Suture Passer (2-0) is an accessory of the Anchor System. The Anchor System is indicated for visualization of the surgical field in any area of the body cut open during a surgical procedure. When used in the cervical, thoracic, or lumbar spine either from an anterior or posterior direction, for example, the Anchor Endoscope and accessories are intended to aid the surgeon’s visualization of the surgical area and allow him/her to perform any type of surgical spinal procedure such as herniated disc repair, visualization of the circumferential decompression of the nerve roots, aiding in the search and removal of nucleus material, spinal fusion, or insertion of spinal implants. Other examples of generic surgical use of the Anchor System would be for use in the knee, ankle, shoulder, hand, wrist, and temporomandibular joint (TMJ). Patents pending and/or issued.

Media Contact Person:
Ester Kwok
Global Product Manager
ekwok@anchorortho.com
Tel: 647-484-0662 ext 388
Anchor Orthopedics XT Inc.
http://www.anchorortho.com

SOURCE Anchor Orthopedics

Read More
464_main.jpg

Intellijoint Surgical® Completes One Thousand Total Hip Replacement Procedures with intellijoint HIP®

Posted On April 11, 2017 By OrthoSpineNews In Recon, Top Stories /  

WATERLOO, ON, April 11, 2017 /PRNewswire/ – Intellijoint Surgical® is proud to announce that intellijoint HIP® has now – only one year after commercial launch – been used in over 1,000 total hip replacement procedures in the United States, Canada and Australia.  intellijoint HIP® is a novel medical device providing 3D mini-optical navigation for orthopaedic surgeons.  The one thousandth case using intellijoint HIP was completed by Dr. Peter Sculco, Orthopaedic Surgeon, Hospital for Special Surgery in New York City. Surgeons who also performed a procedure using intellijoint HIP the day of this milestone include: Dr. Jeffrey Goldstein, Dr. Alejandro Gonzalez Della Valle, Dr. Ritesh Shah, and Dr. Jonathan Vigdorchik.

“All surgeons want to provide the best outcome for their patients.  A hip replacement should strive to replicate native anatomy as this best optimizes muscle function and overall recovery.  When it comes to a successful hip surgery, nature knows best and intellijoint HIP provides me with the real-time information I need to better replicate patient anatomy,” commented Dr. Peter Sculco. “Intellijoint empowers me to more accurately restore hip biomechanics which leads to satisfied patients and a rewarding clinical practice.”

To publicly acknowledge and thank the many healthcare professionals involved in early adoption of intellijoint HIP, Intellijoint Surgical has launched 1000 Thanks – a digital collage featuring those who were a part of the first 1,000 procedures. Each photo was taken using intellijoint HIP‘s novel 3D mini-optical camera in a “selfie” style to capture the individual in their work environment. Orthopaedic surgeons, nurses, physician assistants, surgical technicians, clinical coordinators, implant technicians and more from New York, Greater Chicago, Toronto, and surrounding area hospitals all volunteered to participate in this initiative.

“Reaching 1,000 procedures in year one of sales is a significant milestone for our company,” said Armen Bakirtzian, CEO and Co-Founder of Intellijoint Surgical. “We wouldn’t be here without the great teams of surgeons, nurses, OR staff and administrators focused on improving care for their patients.”

Intellijoint continues to grow aggressively within its existing markets and plans to expand to new markets early this summer.

About Intellijoint Surgical:

Intellijoint Surgical® develops and commercializes surgical navigation solutions. Intellijoint’s flagship product, intellijoint HIP® provides surgeons with real-time, intraoperative measurements to ensure proper positioning of orthopaedic implants during Total Hip Arthroplasty. Intellijoint is committed to driving clinical results through the development of solutions that are accessible, fast, and easy-to-use. Guided by a scientific advisory board comprised of Dr. Allan Gross, an orthopaedic surgeon at Mount Sinai Hospital, and members, Dr. Javad Parvizi at Thomas Jefferson University Hospital, Dr. Michael Cross at Hospital for Special Surgery, Dr. Wayne Paprosky at Rush University Medical Center, and Dr. Ran Schwarzkopf at NYU School of Medicine, Intellijoint is setting the new standard in miniature 3D surgical navigation.

Intellijoint Surgical is the recipient of the 2015 North American Frost & Sullivan Enabling Technology Leadership Award and the Futurpreneur Shopify True Grit Award 2016.

For more information, please visit: www.intellijointsurgical.com

SOURCE Intellijoint Surgical Inc.

Related Links

https://www.intellijointsurgical.com/

Read More
Safe_Ortho_Image_1.jpg

Safe Orthopaedics Products Listed by AP-HP Paris Hospitals

Posted On April 11, 2017 By OrthoSpineNews In Spine /  

April 10, 2017

ERAGNY-SUR-OISE, France–(BUSINESS WIRE)–Regulatory News:

SAFE ORTHOPAEDICS (Paris:SAFOR) (FR0012452746 – SAFOR), a company offering an innovative range of sterile implants combined with their single-use instruments for spinal surgery, is today announcing that its principal products for thoracolumbar spinal fusion have been listed by AP-HP (Assistance Publique – Hôpitaux de Paris, the main hospital authority serving Paris and its suburbs).

This listing with AP-HP means that Safe Orthopaedics products are available in 39 hospitals in Paris, including 15 active in spinal surgery, together accounting for around one-quarter of the French market.

To support the growing activity in the Paris region and capitalize on this listing from the outset, the Company has hired a sales manager for the Paris region, backing up the teams already covering largely south-east and south-west France.

Upon the introduction of its products, Safe Orthopaedics had initially decided to focus on development in the regions with the assistance of expert salespeople possessing very strong local roots in a bid to firmly establish its credibility. The addition of dedicated sales coverage for the Paris region represents another crucial stage in the Company’s development.

Aside from the AP-HP approval, the new sales manager for the Paris region will be able to build on the relationships already established with hospitals in the Paris region. These include Kremlin-Bicêtre teaching hospital where it has conducted a trial demonstrating the benefits of Safe Orthopaedics’ single-use instruments for spinal surgery2.

All the thoracolumbar ranges have been successfully listed with AP-HP. SteriSpine PS and SteriSpine LC can cover requirements for the bulk of trauma and degenerative surgeries performed at these hospital facilities.

“We are proud of the work done by our sales teams, which has resulted in our products being listed by AP-HP Paris hospitals. This represents a very important step forward in the expansion of our business. It will boost our sales not only in the Paris region but also in all the major public and private hospitals in France, given the value of such a listing.” said Pierre Dumouchel, Chief Executive Officer of Safe Orthopaedics.

About AP-HP

AP-HP is a globally renowned and leading European hospital authority. Every year, its 39 hospitals treat 8 million sick people, providing consultations, emergency and scheduled in-patient treatment and in-home healthcare. It provides public healthcare services round-the-clock, which it regards both as a duty and a source of pride. AP-HP is the Paris region’s leading employer, with its workforce of 100,000 doctors, research scientists, paramedics, administrative and blue-collar staff. For further information: www.aphp.fr

Next Financial Release

Full-year 2016 results: April 28, 2017 (after market close)

About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics is a French medical technology company that aims to make spinal surgeries safer by using sterile implants and associated single-use instruments. Through this approach, these products eliminate all risk of contamination, reduce infection risks and facilitate a minimally-invasive approach for trauma and degenerative pathologies—benefiting patients. Protected by 17 patent families, the SteriSpineTM kits are CE-marked and FDA approved. The company is based at Eragny-sur-Oise (Val d’Oise department), and has 30 employees.

For more information, visit: www.SafeOrtho.com

1 Source: Safe Orthopaedics
2 See the “A Randomized Study Confirms the Benefits of Safe Orthopaedics’ Products in a Leading French Teaching Hospital” press release dated October 20, 2016.

Contacts

Safe Orthopaedics
Thierry Lambert, Tél.: +33-(0)1-34-21-50-00
CFO
investors@safeorthopaedics.com
or
NewCap
Julien Perez / Valentine Brouchot
Investor Relations
Nicolas Merigeau
Media Relations
Tél.: +33-(0)1-44-71-94-94
SafeOrtho@newcap.eu

Read More
DJO-Global.jpg

IPG and DJO Announce Partnership to Deliver High Quality Affordable Care

Posted On April 11, 2017 By OrthoSpineNews In Financial, Recon, Top Stories /  

April 11, 2017

ATLANTA–(BUSINESS WIRE)–IPG, the industry-leading provider of Device Benefit Management solutions, announced an innovative new partnership with DJO Global, Inc. and its Surgical Division. DJO Global is a leading global provider of medical technologies designed to get and keep people moving. With DJO’s broad range of products, used for rehabilitation, pain management, physical therapy and surgical reconstruction, the partnership further enables high quality, cost effective care and supports the delivery of value based care for high cost surgical procedures for IPG’s health plan clients and patients.

“As health plans look to set up the right structure that aligns incentives in support of value based reimbursement, the IPG program truly sets the stage to drive quality and affordability from optimal device selection and utilization, and site of care to truly impact surgical costs. DJO Surgical’s products contribute to lowering surgical costs and patient out of pocket costs. A true win-win,” said Mark Russell, Senior Vice President of Sales, Marketing and Commercial Logistics for DJO Surgical.

The IPG platform enables surgeons, facilities and device manufacturers to play an active role in the delivery of cost effective surgical care. DJO’s focus on value-driven implant systems and state-of-the-art technology strongly aligns with IPG’s mission of ensuring and enabling the delivery of high quality, cost effective surgical care.

“We are thrilled to work with innovative high quality manufacturers like DJO, who focus on lowering total episodic care through surgical efficiency for patients and health plans,” said Vince Coppola, President and CEO of IPG. “These partnerships continue to expand our ability to deliver on our cost and quality objectives for our health plan clients. Since our programs align incentives and goals between surgeons, facilities, health plans and manufacturers, DJO is now part of the team with the important mission of making health care more affordable.”

DJO’s surgical portfolio includes a full suite of advanced solutions for hip, knee and shoulder arthroplasty with an emphasis on incorporating modern technology while capturing both surgical and cost efficiencies that will be accessible to IPG’s expansive network of direct partnering facilities and surgeons.

About DJO Global

DJO Global is a leading global provider of medical technologies designed to get and keep people moving. The Company’s products address the continuum of patient care from injury prevention to rehabilitation after surgery, injury or from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopaedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopaedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO Global’s products are marketed under a portfolio of brands including Aircast®, Chattanooga, CMF™, Compex®, DonJoy®, ProCare®, DJO® Surgical, Dr. Comfort® and Exos™. For additional information on the Company, please visit www.DJOglobal.com.

About IPG

IPG is the leading provider of Device Benefit Management solutions, working with health plans, manufacturers, providers, surgical facilities and patients across the country to improve quality and reduce costs for surgical procedures through optimization of the most effective site of care and device selection, resulting in more affordable high-quality care to consumers. For more information about IPG, call us at 866.753.0046, or visit us on the web at www.ipg.com.

Contacts

IPG
Kerry Lee Perry, 866-753-0046
kperry@ipg.com
or
DJO Surgical
A DJO Global Company
Kristin Barnebey, 512-826-5284
Kristin.Barnebey@DJOglobal.com

Read More